Idera Pharmaceuticals is a biopharmaceutical company focused on the acquisition, development and ultimate commercialization of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet needs.

Furthering our commitment to this goal, in September 2022 Idera merged with Aceragen, Inc., a privately-held biotechnology company addressing rare, orphan pulmonology and rheumatology diseases that typically have no treatment. To learn more about Aceragen, visit www.Aceragen.com.